Purespring Therapeutics

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. Purespring Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $81.6 million. It has raised $165 million.

Last price · $/share
—
Implied valuation
$81.6M
Total raised
$164.7M
Last round
—

Who backs Purespring Therapeutics?

6 investors
InvestorType
British Business BankOther
Sofinnova PartnersVenture capital
ForbionVenture capital
Gilde HealthcarePE / buyout
University of Bristol—
Syncona—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Purespring Therapeutics investors

6 investors are on record for Purespring Therapeutics, including British Business Bank, Sofinnova Partners, Forbion and Gilde Healthcare.

Free account
More of Purespring Therapeutics with a free account
  • ·Watch Purespring Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 6 firms already write checks for companies like Purespring Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View